Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
07:30am, Monday, 09'th Jun 2025
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Ad
Dynavax Comments on Glass Lewis Recommendation
04:59pm, Wednesday, 04'th Jun 2025
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best In
Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies
09:27am, Wednesday, 04'th Jun 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
04:10pm, Wednesday, 28'th May 2025
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod
Deep Track Capital Comments on ISS Recommendation
06:12pm, Friday, 23'rd May 2025
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DV
ISS backs Dynavax directors in board fight with Deep Track Capital
01:54pm, Friday, 23'rd May 2025
Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Trac
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleadin
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
11:48pm, Wednesday, 21'st May 2025
Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balance
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Toda
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
01:00pm, Thursday, 08'th May 2025
Dynavax Technologies (DVAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum
04:45pm, Wednesday, 07'th May 2025
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All F
Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript
07:34pm, Tuesday, 06'th May 2025
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ry
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
06:15pm, Tuesday, 06'th May 2025
Dynavax Technologies (DVAX) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.07 per share a year ago.
Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs
04:01pm, Tuesday, 06'th May 2025
Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growth Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in Q3 2025 New pand
